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ABSTRACT
Cell-death-inducing DFF45-like effector A (CIDE-A)
belongs to a family of proapoptotic proteins, the
expression of which is highly restricted in human
tissues and cells. Here, the core region of the human
CIDE-A promoter was characterized. Surprisingly,
two Sp1/Sp3-binding sites, rather than tissue-
specific transcription factors, were found to be
required for the promoter activity. Although the
ubiquitously expressed Sp1 and Sp3 were crucial,
they alone could not adequately regulate the
specific expression of CIDE-A. We found that the
expression of CIDE-A was further regulated by CpG
methylation of the promoter region. By performing
bisulfite sequencing, we observed dense CpG
methylation of the promoter region in tissues and
cells with low or no expression of CIDE-A but not in
tissues with high level of CIDE-A expression. In vitro
methylation of this region showed significantly
reduced transcriptional activity. Treatment of
CIDE-A-negative cells with 5-aza-2’-deoxycytidine
demethylated the CpG sites; this opened the closed
chromatin conformation and markedly enhanced
the binding affinity of Sp1/Sp3 to the promoter
in vivo, thereby restoring CIDE-A expression. These
data indicated that CpG methylation plays a crucial
role in establishing and maintaining tissue- and cell-
specific transcription of the CIDE-A gene through
the regulation of Sp1/Sp3 binding.
INTRODUCTION
Apoptosis, a morphologically distinct form of pro-
grammed cell death, is an evolutionary highly conserved
phenomenon that plays an important role in the
regulation of cellular activities in eukaryotes (1).
Recently, a novel family of cell-death-inducing DFF45
(DNA fragmentation factor-45)-like eﬀector (CIDE)
proteins has been identiﬁed. The CIDE family includes
three members (CIDE-A, CIDE-B and CIDE-C) in
humans, and their mice homologues have also been
identiﬁed (2–4). CIDE-A was initially identiﬁed by virtue
of its sequence similarity to the N-terminal region of the
apoptotic DNA fragmentation factors DFF40/CAD and
DFF45/ICAD. The overexpression of CIDE-A in various
cell lines induces caspase-independent cell death asso-
ciated with the fragmentation of DNA (3). In addition to
cell-death induction, recent studies have indicated a
correlation between CIDE-A and obesity. CIDE-A-null
mice are resistant to diet-induced obesity and diabetes and
display higher metabolic rate and lipolysis in the brown
adipose tissue than their wild-type littermates (5). In obese
women undergoing weight reduction through a low-
calorie diet, the CIDE-A gene is the highest upregulated
gene in the subcutaneous adipose tissue among 8000
investigated genes (6). Furthermore, CIDE-A is consid-
ered to play a human-speciﬁc role in lipolysis regulation
and metabolic complications of obesity, which is at least
partly mediated by cross-talk between CIDE-A and tumor
necrosis factor-a (TNF-a) (7). Thus, CIDE-A is also
considered as a strong candidate gene for obesity and
could serve as a novel target for therapeutic intervention
of obesity and Type II diabetes (7–9).
According to the previous reports, the expression of
CIDEs is strongly tissue and cell speciﬁc. In addition to
high levels of expression in the adipose tissue, CIDE-A
transcripts of various lengths are present in diﬀerent
human tissues such as the heart, muscle and thymus (3,7).
The mice CIDE-A is expressed abundantly in the brown
adipose tissue and could be transcriptionally activated by
proliferator-activated receptor-a (PPARa) and PPARg
(10). Other CIDE genes also have multiple transcripts
with diﬀerent levels of tissue- and cell-speciﬁc expression.
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expressed in the liver and spleen tissues (3), while the
expression of the human CIDE-C gene was detected in the
small intestine, heart, colon and stomach (4). Studies on
the human CIDE-B gene showed that the cell-speciﬁc
expression of two transcripts of CIDE-B was driven by
two diﬀerent promoters through epigenetic and genetic
mechanisms (11). The expression of the adipocyte-speciﬁc
gene FSP27, a member of the mice CIDE family, was
regulated by CCAAT/enhancer-binding protein (C/EBP)
and other C/EBP-like transcription factors (2). Thus, the
transcription of the CIDE genes appears to be regulated in
a strictly tissue- and cell-speciﬁc manner. However, the
molecular mechanisms that regulate the tissue- and cell-
speciﬁc transcription of the human CIDE-A gene have not
been elucidated.
In the present study, we investigated the transcriptional
regulation of the human CIDE-A gene in human tissues
and several cancer cells and found that the ubiquitously
expressed transcription factors Sp1 and Sp3 were crucial
for CIDE-A promoter activity. In addition, we found
that DNA methylation of the CIDE-A promoter played
an important role in regulating tissue- and cell-speciﬁc
expressionofthisgenebyinterferingwithSp1/Sp3binding.
MATERIALS AND METHODS
Samples ofhuman tissues andcell lines
Human adipose and liver tissue samples were obtained
from Zhongshan Hospital (Shanghai, China). Informed
consent was obtained from the patients. The total RNA
and genomic DNA of human heart, spleen, kidney, lymph
node, lung and stomach tissues were purchased from
Shenzhen Innogent Bioscience Inc. All cell lines used in
this study were obtained from the Cell Bank of the
Chinese Academy of Sciences (Shanghai, China) and were
maintained in our laboratory. BEL-7404 cells (human
hepatocellular carcinoma), U2OS cells (human osteosar-
coma), HEK-293T cells (human embryonic kidney) and
Hela cells (human cervical carcinoma) were grown in
Dulbecco’s modiﬁed Eagle’s medium (DMEM, Gibco
BRL, Grand Island, NY, USA) supplemented with 10%
(v/v) fetal bovine serum (FBS, Gibco BRL). Saos-2 cells
(human osteosarcoma) were grown in McCoy’s 5A
medium (Gibco BRL) supplemented with 15% FBS. All
media were supplemented with 100 units/ml penicillin and
100mg/ml streptomycin. All the cells were cultured at 378C
in 5% CO2.
RNA analysis
Total RNA was extracted from cultured cells using TRIzol
reagent (Invitrogen, Carlsbad, CA, USA). Total RNA
(5mg)wasreversetranscribedusingoligo(dT)18primerand
SuperScript II First-Strand Synthesis System (Invitrogen)
in a reaction volume of 20ml according to the manufac-
turer’s instructions. PCR was performed using two pairs of
primers. The ﬁrst primer pair was used for amplifying
a 305-bp CIDE-A gene fragment (CIDE-A-F, 50-AAGAG
GTCGGGAATAGCGAGAGTC-30; CIDE-A-R, 50-CT
GCATCCCTATCCACACGTGAACC-30). The second
primer pair was used for amplifying a 532-bp GAPDH
gene fragment as an internal control (GAPDH-F, 50-AGG
TCGGAGTCAACGGATTTG-30; GAPDH-R, 50-GTGA
TGGCATGGACTGTGGT-30). The ampliﬁcation condi-
tions for CIDE-A were as follows: initial denaturation at
948C for 5min; 30 cycles of 1min at 948C, 1min at 588C
and 30s at 728C; and a ﬁnal extension step for 10min at
728C. For GAPDH, the following PCR conditions were
applied: 1 cycle at 948C for 5min; 25 cycles of 1min at
948C,1minat558Cand1minat728C;andaﬁnalextension
step for 10min at 728C. The PCR products were electro-
phoresed on a 1.5% agarose gel.
CpGisland prediction
The presence of a putative CpG island in proximity to the
CIDE-A gene was analysed using the CpG Island Searcher
program (http://www.uscnorris.com/cpgislands/cpg.cgi)
(12) with the default setting (%GC >55%, ObsCpG/
ExpCpG >0.65, length >500bp).
Plasmid constructs
The 50 region ( 1556 to  13, relative to the translation
start site of the human CIDE-A gene) of human CIDE-A
was ampliﬁed by PCR using high-ﬁdelity LA Taq
polymerase (Takara, Dalian, China) from human genomic
DNA isolated from HEK-293T cells and inserted into the
pGL3-Basic vector (Promega, Madison, WI, USA).
Nested deletions of the CIDE-A promoter region were
carried out using the plasmid p( 1556/ 13) as the
template by PCR ampliﬁcations, and the sequences of
the products were conﬁrmed by direct sequencing. Primers
for nested deletions are: -1556-F (50-CCCTCGAGCTAC
AGGTGCTCGCCGTCAT-30); -1112-F (50-CCCTCGAG
ACCACGGTGACCCTTTCTGA-30); -892-F (50-CCCTC
GAGCCGAGTCCCACCCCTCAACA-30); -640-F (50-C
CCTCGAGTCACTGTCCCCAAATGCTCA-30); -438-F
(50-CCCTCGAGGAGGCAAGTGGCGCTCACAT-30);
-250-F (50-CCCTCGAGGGGCTTCCAAGGTCCTCGG
T-30); -196-F (50-CCCTCGAGGCTGCGGGAGCCAGG
ACGAC-30); -137-F (50-CCCTCGAGGGAGAGCTCG
TGCCAAAACG-30); -13-R (50-CCAAGCTTTAGCGG
GCCTGGAGGTCTGT-30); -137-R (50-CCAAGCTTA
CCGCCGAGGATCGCGACTT-30)
Site-directed mutagenesis of two Sp1/Sp3 response
elements (RE1,  76/ 70; RE2,  70/ 64) in plasmid
p( 137/ 13) was performed by PCR (GGGCGGG in
Sp1/Sp3 RE was changed to GGACAAG), and the
mutagenesis was conﬁrmed by direct sequencing. Primers
for site-directed mutations are: Spm1-R (50-CGGC
CCCGCCCTTGTCCGCCTGCCAGCCCCGCGAA-30);
Spm1-F (50-TTCGCGGGGCTGGCAGGCGGACAAG
GGCGGGGCCG-30); Spm2-R (50-CGGCCTTGTCCC
CGCCCGCCTGCCAGCCCCGCGAA-30); Spm2-F
(50-TTCGCGGGGCTGGCAGGCGGGCGGGGACAA
GGCCG-30); Spm3-R (50-CGGCCTTGTCCTTGTCC
GCCTGCCAGCCCCGCGAA-30); Spm3-F (50-TTCGC
GGGGCTGGCAGGCGGACAAGGACAAGGCCG-30)
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For transient transfections, Hela and HEK-293T cells
were plated onto 24-well plates 1day before transfection
at a density of 5 10
4 and 2 10
5 cells/well, respectively.
Cells were transfected with 0.4mg of various luciferase
constructs by using LipofectAMINE
TM reagent (Gibco
BRL) according to the manufacturer’s instructions. The
pRL-TK plasmid (Promega; 40ng/sample) containing the
Renilla luciferase gene driven by the herpes simplex virus
thymidine kinase promoter was cotransfected with the
constructs, and the luciferase activity was normalized. The
preparation of cell lysates and measurements of luciferase
activity were performed using the Dual Reporter assay
system (Promega) and Lumat LB 9507 luminometer
(EG & G Berthold, Berlin, Germany) according to the
manufacturer’s instructions. All transfections were per-
formed three times in triplicate.
Electrophoretic mobility shift assays
Nuclear extracts were prepared from Hela cells as
described by Gazzoli and Kolodner (13). The wild-type
probe of the CIDE-A promoter (from  91 to  57) was
generated by annealing two complementary oligonucleo-
tides (SpWT: 50-GCGGGGCTGGCAGGCGGGCGGG
GGCGGGGCCGCCG-30;5 0-GTGCGGCGGCCCCGC
CCCCGCCCGCCTGCCAGCCC-30, the core sequence
of the Sp1/Sp3-binding site is underlined) and ﬁlling the 30
recessive ends by repair synthesis with dATP, dTTP,
dGTP, [a-
32P]dCTP and the Klenow fragment of DNA
polymerase I (Takara). The mutated probe of the CIDE-A
promoter was generated by the same procedure, except
that several oligonucleotides with mutations (SpM1:
50-GCGGGGCTGGCAGGCGGACAAGGGCGGGGC
CGCCG-30,5 0-GTGCGGCGGCCCCGCCCTTGTCCG
CCTGCCAGCCC-30; SpM2: 50-GCGGGGCTGGCAG
GCGGGCGGGGACAAGGCCGCCG-30,5 0-GTGCGG
CGGCCTTGTCCCCGCCCGCCTGCCAGCCC-30;
SpM3: 50-GCGGGGCTGGCAGGCGGACAAGGACA
AGGCCGCCG-30,5 0-GTGCGGCGGCCTTGTCCTTG
TCCGCCTGCCAGCCC-30, mutations are shown in
bold) in the core sequence of the Sp1/Sp3-binding site
were used. Nuclear extracts containing 10mg of the protein
were preincubated in 20ml of binding buﬀer [10mM Tris–
HCl (pH 7.5), 50mM NaCl, 1mM MgCl2, 0.5mM
EDTA, 0.5mM dithiothreitol, 50mg/ml poly(dI-dC) 
poly(dI-dC), and 4% glycerol] with or without unlabeled
competitor (100-fold molar excess). For supershift assays,
1mg of antibodies or rabbit IgG (Sigma) was added to the
preincubation mixture. After 30-min preincubation on ice,
the DNA probe (20000 cpm) labeled with [a-
32P] dCTP
was added, and the samples were incubated at room
temperature for 30min. The reaction mixtures were
resolved on 4% polyacrylamide gels. The gels were dried
and subjected to PhosphorImager analysis using a Storm
860 system and ImageQuant TL software (Amersham
Biosciences, Sunnyvale, CA, USA). Antibodies used in
supershift assays were rabbit polyclonal antibodies against
Sp1 (sc-59X) and Sp3 (sc-644) from Santa Cruz
Biotechnology (Santa Cruz, CA, USA).
Sodium bisulfite genomicsequencing
Sodium bisulﬁte modiﬁcation of genomic DNA was
performed as described previously (14). Brieﬂy, 2mgo f
genomic DNA, which had been digested with EcoRI and
BglII, was denatured in 0.3M NaOH for 15min at 378C
and then treated with 3M sodium bisulﬁte (Sigma, St
Louis, MO, USA) and 10mM hydroquinone (Sigma) for
16h at 508C. The DNA was then desalted using the
Wizard DNA Clean-Up System (Promega), desulpho-
nated in 0.3M NaOH, and precipitated. The treated DNA
was ampliﬁed by PCR in a 50-ml reaction volume using the
bisulﬁte-speciﬁc primers (BS-F, 50-TTGGTAAGTGATT
AAAAGAGATT-30 and BS-R, 50-CCTAATTATTTCT
CCTACATAATC-30). The ampliﬁcation conditions for
the 325-bp DNA fragment were as follows: 948C for
5min; 35 cycles of 1min at 948C, 1min at 508C, 30s at
728C; and a ﬁnal extension step for 10min at 728C. The
puriﬁed PCR products were cloned into the pMD18-T
vector (Takara), and eight clones were picked out and
sequenced for each sample.
Nuclease accessibility assay
The nuclei of cells were prepared as described previously
(15) and digested with the restriction enzyme AluI (New
England Biolabs, Beverly, MA, USA). DNA was then
extracted from the digested nuclei with the proteinase
K/phenol procedure (16). DNA from the AluI-digested
nuclei was ampliﬁed by PCR using primers P1 and P3 and
electrophoresed on a 2% agarose gel. The absence or
presence of a 238-bp fragment indicated whether AluIi s
accessible to the chromatin in the CIDE-A promoter
region. To assess the input of the chromatin, another
primer, P2, was also included in the PCR reaction
mixture. The amount of AluI-digested chromatin was
represented by the ratio 238:113bp. The primers used were
as follows: P1, 50-GGGCTTCCAAGGTCCTCGGT-30;
P2, 50- ACCGCCGAGGATCGCGACTT-30; P3, 50- TAG
CGGGCCTGGAGGTCTGT-30.
In vitro methylation ofthe critical CIDE-Apromoter region
The CIDE-A reporter construct p( 250/ 13) and the
pGL3-Basic vector were methylated by incubation with
SssI methylase (New England BioLabs) for 3h at 378Ci n
the presence of 160mM S-adenosylmethionine. The
methylation status was veriﬁed by digestion with HhaI, a
methylation sensitive enzyme.
5-aza-2’-Deoxycytidine and trichostatin Atreatment
Cells were treated with 1 and 10mM 5-aza-20-
deoxycytidine (5-aza-dC, Sigma) for 72h or with 300nM
trichostatin A (TSA) (Sigma) for 24h, as described
previously (16,17). Brieﬂy, the cells were plated onto
6-well plates at a density of 2 10
4 at 24h before
treatment. The cells were then treated with 5-aza-dC or
TSA. The same volume of dissolving stock was used as a
negative control. Due to the chemical instability of 5-aza-
dC, fresh inhibitor was added after every 24h for a total of
72-h incubation.
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Chromatin immunoprecipitation (ChIP) assay was per-
formed using the ChIP-IT kit (Active Motif, Carlsbad,
CA, USA) according to the manufacturer’s protocol.
Brieﬂy, cells were treated with 1mM 5-aza-dC for 3 days,
along with a negative control. Formaldehyde was added
to the cells at a ﬁnal concentration of 1% and incubated
for 10min at room temperature. The cells were pelleted,
resuspended in SDS lysis buﬀer (1% SDS/10mM EDTA/
50mM Tris–HCl, pH 8.1), and incubated on ice. The
lysate samples were sonicated, and debris was removed by
centrifugation. After obtaining the chromatin solution,
salmon sperm DNA–protein G agarose slurry was added
and incubated for 2h at 48C. Beads were pelleted by
centrifugation, and the supernatants were incubated
overnight at 48C with 2mg of speciﬁc antibodies
[anti-Sp1 (sc-59X) and anti-Sp3 (sc-644), Santa Cruz
Biotechnology; anti-acetyl-Histone H3 K9 and anti-
dimethyl-Histone H3 K9, Upstate Biotechnology, Inc.].
The resultant DNA complexes were collected using a
salmon sperm DNA–protein G agarose slurry. After
reverse cross-linking of protein–DNA with 5M NaCl
followed by RNase A treatment, DNA was puriﬁed using
mini-columns provided with the kit. The puriﬁed DNA
was ampliﬁed by the promoter-speciﬁc primers (ChIp-F,
50-GGGCTTCCAAGGTCCTCGGT-30 and ChIp-R,
50-CACAGCCTCTTAAAGTGCGG-30), and PCR was
performed under the following conditions: 1 cycle at 948C
for 5min; 35 cycles of 1min at 948C, 1min at 588C, 30s at
728C; and a ﬁnal extension step for 10min at 728C. The
PCR products were analysed by electrophoresis on a 2%
agarose gel.
RNA interference and westernblot analysis
RNA interference was achieved by using siRNA pools of
Sp1 and Sp3 (Genepharm Research Shanghai, China).
A functional non-targeting siRNA was used as a control
for potential non-speciﬁc eﬀects caused by siRNA
transfection. HEK-293T cells were plated in 6-well
dishes and grown to  60% conﬂuence. Cells were then
transfected using Lipofectamine 2000 according to the
manufacturer’s protocol (100nM of each siRNA pool).
Forty-eight hours after transfection, HEK-293T cells
were harvested for detection of Sp1 and Sp3 proteins.
Total cell samples were harvested by applying 2 SDS
Laemmli sample buﬀer directly on to cell monolayers after
three washes with PBS. Electrophoresis, transfer of
proteins on to nitrocellulose membranes and blocking of
membranes were performed as described previously (18).
Antibodies speciﬁcally against Sp1 (anti-Sp1, sc-59X), Sp3
(anti-Sp3, sc-644) and tubulin (Ab-4; NeoMarkers,
Freemont, CA, USA) were incubated with the membranes
for 1h at room temperature. Secondary antibody [goat
anti-rabbit and donkey anti-goat IgG conjugated to
horseradish peroxidase (Santa Cruz)] was used at a
dilution of 1:2000, and incubated with membranes for
1h at room temperature. Proteins revealed by western
blotting were visualized by chemiluminescence.
RESULTS
Tissue-and cell-specific expression of CIDE-Aand the
structure ofthe CIDE-Alocus
To conﬁrm that the transcription of the CIDE-A gene is
regulated in a cell- and tissue-speciﬁc manner, the
expression of the CIDE-A gene in ﬁve cancer cell lines
and eight human tissues was measured by reverse
transcription-PCR using the GAPDH gene as an internal
control (Figure 1A). A high level of expression of the
CIDE-A gene was observed in adipose, lymph node and
heart tissues, while no expression was detected in liver,
kidney, lung, spleen and stomach tissues. Furthermore,
the expression level in HEK-293T and U20S cells was very
low and in Hela, BEL-7404 and Saos-2 cells was
undetectable.
The genomic structure of CIDE-A was analysed and is
shown in Figure 1B. The gene corresponding to the
reported cDNA that encode CIDE-A (GenBank accession
number NM_001279) is mapped to chromosome 18p11.
The CIDE-A transcript contains 5 exons (exons 1, 2, 3, 4
and 5). The CpG Island Searcher program revealed a CpG
island (from  619 to 870) spanning the 50 upstream area
and exon 1 of the CIDE-A gene. To simplify the
nomenclature, we have attributed position number +1
to the translation start site of the CIDE-A gene.
Identification of thecritical promoter region of CIDE-A
To investigate the transcriptional regulation of the
CIDE-A gene, we identiﬁed the promoter region of this
gene. We ﬁrst constructed a luciferase reporter plasmid
p( 1556/ 13) that contained a 1544-bp genomic DNA
fragment spanning the 50 upstream region of CIDE-A.
This plasmid was used for transient transfection of Hela
and HEK-293T cells. HEK-293T cells expressed very low
level of CIDE-A, whereas Hela cells did not (Figure 1A).
The cloned fragment exhibited obvious promoter activity
Figure 1. Cell- and tissue-speciﬁc expression and genomic structure of
the human CIDE-A gene. (A) RT-PCR analysis of CIDE-A expression
in ﬁve human cell lines and eight human tissues as indicated. Five
micrograms of total RNA from cells and tissues was analysed by
RT-PCR using primers speciﬁc for CIDE-A CDS. A 305-bp fragment
of CIDE-A CDS was ampliﬁed. A 532-bp fragment of the GAPDH
gene was used as a positive control for RNA integrity. (B) Structure of
the human CIDE-A locus. Boxed arrows represent published cDNAs
encoding known proteins. The open, grey and black boxes represent the
untranslated regions, ORFs and predicted CpG island, respectively.
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sequence was isolated (Figure 2A). Next, we developed a
series of deletion constructs to identify the minimal
promoter required for activation. Deletion in the 30
region from  13 to  137 completely abolished the activity
of the reporter gene and enabled to locate the minimal
promoter within the 125-bp region between positions
 137 and  13 (Figure 2A). The nucleotide sequence of
the minimal promoter region is shown in Figure 2B and
deposited in GenBank under the accession number
EF672106. This sequence is located in the CpG island.
We searched for transcription factor binding sites using
the MatInspector program and found consensus
sequences for the binding of Sp1/Sp3, E2F and Nuclear
factor Y. Although Hela cells did not express CIDE-A, the
diﬀerent constructs exhibited obvious promoter activity,
regardless of the CIDE-A expression status, suggesting
additional mechanisms of CIDE-A gene regulation in vivo.
Sp1/Sp3-binding motifs areimportant forCIDE-A
promoter activity
As shown in Figure 2B, two putative binding sites for Sp1/
Sp3 were found in the minimal promoter region of
CIDE-A. To determine whether the Sp1/Sp3-binding
elements are important in CIDE-A promoter activity, we
generated several constructs of p( 137/ 13) that con-
tained mutations in the Sp1/Sp3-binding site by site-
directed mutagenesis. The reporter constructs containing
mutated sequences were then transfected into Hela and
HEK-293T cells and assayed for promoter activities. The
mutation induced in either of the Sp1/Sp3 sites decreased
the promoter activity level to  50% of that of the wild
type, whereas the activity decreased to a basal level when
both the Sp1/Sp3-binding sites were mutated (Figure 3).
These results clearly indicate that both the Sp1/Sp3-
binding sites are essential for the activity of the CIDE-A
minimal promoter.
Figure 2. Identiﬁcation of the minimal promoter region of the CIDE-A gene. (A) Identiﬁcation of the critical CIDE-A promoter region using
luciferase assays. The CIDE-A transcripts (open and grey boxes) and CpG island (black box) are indicated. Hela cells (black bars) and HEK-293T
cells (grey bars) were transfected with the indicated constructs and assayed for luciferase activity 24h after transfection. Numbers above the
constructs indicate the positions relative to the translation start site of CIDE-A. The activity of each promoter construct is shown as the luciferase
activity relative to that of the pGL3-Basic vector (a promoterless vector). Values were normalized for transfection eﬃciency by cotransfection with
the Renilla expression plasmid and are shown as means SD for three independent experiments. (B) Nucleotide sequence of the CIDE-A minimal
promoter region. The E2F and nuclear factor Y response elements are shown in boxes. The consensus sequences for two potential Sp1/Sp3-binding
sites are underlined.
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to thecritical CIDE-A promoter region
To directly demonstrate that Sp1 and Sp3 bind to the
putative binding site within the critical CIDE-A promoter
region, EMSA was performed using a-
32P-labeled oligo-
nucleotides spanning the two putative Sp1/Sp3-binding
sites with nuclear extracts generated from Hela cells.
Shifted complexes were observed when the labeled wild-
type probe was used (Figure 4, lane 2); these complexes
were eliminated by the addition of 100-fold molar excess
of unlabeled wild-type probe (Figure 4, lane 3). EMSA
was also performed on mutant probes to understand the
contribution of each of the Sp1/Sp3-binding sites to the
observed binding patterns. Any mutation in the two Sp1/
Sp3-binding sites (SpM1 or SpM2 probe) slightly
decreased the level of complex formation, while these
bands were not observed when using the SpM3 probe with
mutations in both the Sp1/Sp3-binding sites (Figure 4,
lanes 4–6). To further conﬁrm the speciﬁc binding of Sp1/
Sp3 to the CIDE-A minimal promoter, supershift assay
was performed using anti-Sp1 and anti-Sp3 antibodies.
The slowest migrating protein–DNA complex was super-
shifted by anti-Sp1 antibodies (Figure 4, lane 8), whereas
the rapidly migrating bands were supershifted by anti-Sp3
antibodies (Figure 4, lane 9). However, no supershift was
observed when control IgG was used instead of speciﬁc
antibodies (Figure 4, lane 7). The EMSA results demon-
strated that Sp1 and Sp3 bound speciﬁcally to the two
Sp1/Sp3-binding sites in the CIDE-A minimal promoter.
Methylation statusof CpG sitesin theCIDE-A promoter
Sp1 and Sp3 are ubiquitously expressed transcription
factors; therefore, they might not be responsible for the
tissue- and cell-speciﬁc expression of the CIDE-A gene.
The CIDE-A promoter is located in a CpG island
(Figure 5A), and the Sp1/Sp3-binding sites in the
CIDE-A gene promoter contain a CpG dinucleotide, a
potential target for DNA methylation in mammals; this
suggests that DNA methylation may play a role in the
regulation of tissue- and cell-speciﬁc expression of the
CIDE-A gene. We then examined the methylation status
of 31 CpG sites in the promoter region by sodium bisulﬁte
sequencing (Figure 5B). The results from the sequences of
eight clones showed that in CIDE-A expressed tissues the
overall percentage of methylated CpG sites was very low,
only  7% in adipose and  9% in heart, indicating the
CpG sites in CIDE-A promoter region were unmethylated
in adipose and heart tissues; In contrast, in tissues that did
Figure 4. Speciﬁc binding of Sp1 and Sp3 to the critical CIDE-A
promoter region. The binding of Sp1 and Sp3 to the CIDE-A core
promoter was determined by electrophoretic mobility shift analysis
(EMSA). By using
32P-labeled 35-bp double-stranded oligonucleotides
containing wild or mutated Sp1/Sp3-binding sites as probes, EMSAs
were performed with the same amount of nuclear extracts (NE) from
Hela cells, and the products were separated on a 4% polyacrylamide
gel (lanes 2–10). Lane 1, free probe; lane 2,
32P-labeled wild-type Sp1/
Sp3 consensus oligonucleotides were mixed with nuclear proteins;
lane 3, the same reaction was performed as that in lane 2, except for the
presence of a 100-fold excess of unlabeled wild-type Sp1/Sp3 consensus
oligonucleotides as a competitor; lanes 4–6, binding assays of
32P-labeled mutant-type Sp1/Sp3 consensus oligonucleotides mixed
with nuclear proteins; lanes 7–10, 1mg each of IgG, anti-Sp1, anti-
Sp3 or both anti-Sp1 and anti-Sp3 antibodies were added to the
binding reaction mixtures with
32P-labeled wild-type probe.
Figure 3. Sp1/Sp3-binding motifs are important for CIDE-A promoter
activity. The eﬀect of Sp1/Sp3-binding site on the regulation of CIDE-
A promoter activity is shown. Values of luciferase activities due to the
wild-type construct p( 137/ 13) and the mutated constructs (Spm1,
Spm2 and Spm3) in Hela cells (black bars) and HEK-293T cells (grey
bars) are shown as means SD for three independent experiments, each
of which was performed using triplicate samples. Mutations are shown
in bold above the histogram.
Nucleic Acids Research,2008, Vol. 36,No. 1 335not express CIDE-A (liver, spleen and stomach), the
percentage of methylated CpG sites was higher, about
73%, 63% and 57%, respectively, indicating the hyper-
methylated CpG sites in CIDE-A absent expressed tissues.
In the cells in which CIDE-A was silenced (Hela and BEL-
7404), a high degree of methylation was observed at each
CpG site, including the Sp1/Sp3-binding sites. However, in
HEK-293T cells, that with a lower expression of CIDE-A,
the methylation patterns were more mosaic, in eight clones
sequenced we detected one clone with lower percentage of
methylation ( 55%) and other clones were fully methy-
lated. These results revealed that the methylation status of
the CpG dinucleotide reﬂected the tissue and cell speciﬁcity
of the CIDE-A gene expression. The eﬀect of in vitro
methylation on the promoter activity of the CIDE-A gene
was then investigated through transient transfection of
CpG-methylated reporter plasmids into HEK-293T and
Hela cells. We modiﬁed the promoter constructs with SssI
methylase and studied the activity of the methylated
promoter. The luciferase activities of CpG-methylated
reporter plasmids were calculated relative to those of
unmethylated plasmids (unmethylated controls). The
luciferase activity of SssI-methylated pGL3-( 250/ 13)
decreased to  5% and 4% of that of the unmethylated
controls in HEK-293T and Hela cells, respectively
(Figure 5C), suggesting a direct association between CpG
methylation and CIDE-A promoter activity.
Induction of CIDE-A geneexpression by5-aza-dC
To conﬁrm the role of DNA methylation in the CIDE-A
minimal promoter in silencing gene expression, two
Figure 5. Methylation status of CpG sites in the CIDE-A promoter. (A) Schematic diagram of the CIDE-A gene 50 region. Numbers indicate
the positions relative to the translation start site of CIDE-A. The CIDE-A minimal promoter is indicated by the grey box. The position of the 31
CpG sites detected by bisulﬁte sequencing is indicated by a short vertical line. (B) Bisulﬁte sequencing of the CIDE-A promoter region. The genomic
DNA from BEL-7404, Hela and HEK-293T cells and from the liver, spleen, stomach, heart and adipose tissues was treated with bisulﬁte and
ampliﬁed by PCR. The PCR products were then subcloned and sequenced. For each cell line and tissue, the methylation status of 31 CpGs in the
promoter region is shown for eight clones. White and black circles indicate unmethylated and methylated CpGs, respectively. Circles enclosed
by boxes represent the CpGs in the Sp1/Sp3-binding sites. (C) Eﬀect of in vitro methylation on the activity of the CIDE-A promoter. The CIDE-A
promoter-luciferase plasmid p( 250/ 13) was methylated in vitro by SssI methylase. Methylated and unmethylated p( 250/ 13) were then
transiently transfected into Hela and HEK-293T cells and assayed for luciferase activity. Results are shown as percentages of luciferase activity, with
the activity due to unmethylated p( 250/ 13) considered as 100%. The average SD values from three independent experiments performed in
triplicates are shown.
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and one cell line with low-level expression of CIDE-A,
i.e. HEK-293T, were treated with the DNA methyltrans-
ferase inhibitor 5-aza-dC (1 and 10mM). As shown in
Figure 6A, CIDE-A expression was induced in Hela and
BEL-7404 cells after 72h of exposure to the reagent, while
the expression in HEK-293T cells was also increased
signiﬁcantly. The expression of CIDE-A was induced at a
similar level following treatment with 5-aza-dC at 1 and
10mM concentrations. The methylation status in Hela,
BEL-7404 and HEK-293T cells after 5-aza-dC treatment
was then determined by sodium bisulﬁte sequencing.
Methylation was signiﬁcantly decreased in the CIDE-A
critical promoter region in Hela, BEL-7404 and HEK-
293T cells after 5-aza-dC treatment (Figure 6B). The non-
expressing cell lines Hela and BEL-7404 were also treated
with 300nM TSA, a histone deacetylase inhibitor. No
signiﬁcant induction of CIDE-A expression was detected
by reverse transcription-PCR (data not shown), suggesting
that histone deacetylase inhibition by TSA was not
suﬃcient to reactivate the CIDE-A gene that was silenced
following hypermethylation of the promoter region.
5-aza-dC treatment changes the chromatin conformation
aroundtheCIDE-A promoter
Chromatin conformation near the CIDE-A promoter was
studied by the nuclease accessibility assay and ChIP assay.
The nuclei from Hela, BEL-7404 and HEK-293T cells
were digested with the restriction enzyme AluI. DNA
extracted from the nuclei was ampliﬁed by PCR and
analysed by electrophoresis. The ratio 238:113bp repre-
sents the amount of undigested chromatin at the AluI site
( 135/ 130) in the CIDE-A promoter (Figure 7A). This
ratio remained unchanged in these cells when compared
with DNA from undigested nuclei, indicating that the AluI
enzyme was not accessible to the AluI sequence in the
chromatin and that the chromatin conformation was
closed in these cells. After treatment with 1mM 5-aza-dC,
the ratio slightly decreased in BEL-7404 cells, while the
decrease in the ratio was considerably more signiﬁcant in
Hela or HEK-293T cells (Figure 7B); this indicates that
the chromatin around the CIDE-A promoter adopted a
more open conformation after 5-aza-dC treatment.
Figure 7. 5-aza-dC treatment changes the chromatin conformation
around the CIDE-A promoter. (A) Procedure of nuclease accessibility
assay. Nuclei were digested with the restriction enzyme AluI. DNA was
extracted from the nuclei and ampliﬁed by PCR using a set of three
primers (P1, P2 and P3). The decrease in the ratio 238:113bp after AluI
digestion indicates that the chromatin is accessible to AluI.
(B) Chromatin accessibility changes in the critical CIDE-A promoter
region in Hela, HEK-293T and BEL-7404 cells following treatment
with 5-aza-dC. The ratio decreased signiﬁcantly after treating with
1M 5-aza-dC for 3 days. (C) In vivo H3K9 di-methylation and
acetylation levels in the CIDE-A core promoter before and after 3 days’
1M 5-aza-dC treatment were analysed by Chromatin immunoprecipita-
tion (ChIP) assay using antibodies that recognize Ac-H3K9 and di-
methyl H3K9. The normal rabbit IgG was used as a negative control
and Input indicates 5% input DNA, a positive ampliﬁcation control.
Figure 6. Induction of the CIDE-A gene expression by 5-aza-dC. (A)
HEK-293T, Hela and BEL-7404 cells were treated with 1 or 10mM
5-aza-dC. Seventy-two hours after 5-aza-dC treatment, total RNA was
isolated from treated or untreated cells and subjected to RT-PCR to
amplify CIDE-A. The GAPDH gene was used as a positive control
for RNA integrity. (B) Bisulﬁte sequencing to determine the methyla-
tion status of the critical CIDE-A promoter region after 5-aza-dC
treatment. Circles enclosed by boxes represent the CpGs in the Sp1/
Sp3-binding sites.
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close connection between DNA methylation and histone
code modiﬁcations in regions of transcriptional regula-
tion. Dimethylated lysine 9 (di-methyl H3K9) and
acetylated lysine 9 (Ac-H3K9) are two of the most
widely studied histone modiﬁcations. Ac-H3K9 are
typically associated with transcriptionally active promo-
ters, whereas di-methyl H3K9 is associated with repressed
promoters (19). We then utilized chromatin immunopre-
cipitation to determine the levels of the two histone H3
tail lysine modiﬁcations at CIDE-A gene promoters
(Figure 7C). In Hela and BEL-7404 cells, where
CIDE-A is none-expressed, high levels of di-methyl
H3K9 were detected, whereas H3K9 acetylation was not
detectable, consistent with their transcriptionally silent
state. However, in HEK-293T cells, the H3K9 di-
methylation levels of the promoter regions was similar
with Hela and BEL-7404 cells, but having very low levels
of detectable Ac-H3K9, which could explain the very low-
level expression of CIDE-A. After treatment with 1mM
5-aza-dC, H3K9 di-methylation was signiﬁcantly dimin-
ished and H3K9 acetylation was obviously increased in all
cases, which closely linked with gene reactivation. In light
of our data above, we conclude that the activation of the
CIDE-A locus was associated with chromatin remodeling
after demethylation of the promoter region.
CpGmethylation inhibitsthe bindingof Sp1and Sp3tothe
CIDE-Apromoter in vivo
To elucidate the eﬀects of methylation of the CIDE-A
promoter on the binding of Sp1 and Sp3 to the promoter,
ChIP assays were performed in CIDE-A-non-expressing
Hela cells. No detectable Sp1 and very weak Sp3 binding
were observed in Hela cells, whereas treatment with 1mM
5-aza-dC for 72h markedly enhanced the binding aﬃnity
of Sp1 and Sp3 to the CIDE-A promoter along with the
induction of CIDE-A expression (Figure 8). These ﬁndings
suggested that methylation of CpG sites in the CIDE-A
promoter interfered with the binding of Sp1 and Sp3
in vivo.
Knockdownof Sp1and Sp3expression by siRNA reduces
CIDE-Apromoter activity
To conﬁrm the role of Sp1 and Sp3 in the regulation of
CIDE-A promoter activity, we used RNA interference to
knock down Sp1 and Sp3 expression in HEK-293T cells.
Strongly reduced Sp1 and Sp3 protein levels were
observed by Western blot analysis, whereas control
siRNA had no eﬀect on Sp1 or Sp3 protein levels
(Figure 9A). HEK-293T cells were transfected with Sp1
and Sp3 siRNAs individually or simultaneously and then
transfected again with the luciferase reporter plasmid
containing the 125bp CIDE-A core promoter. This
resulted in a 38–58% reduction of luciferase activity in
the presence of Sp1- or Sp3-speciﬁc siRNA compared to
that with control siRNA. In contrast, no inﬂuence on
transcriptional activity of control plasmid p(-1556/-137),
which does not contain the Sp1/Sp3-binding motif, was
observed (Figure 9B). These results indicate that Sp1 and
Sp3 positively regulate the expression of CIDE-A by
transactivating the promoter.
DISCUSSION
Recent studies have shown that CIDE-A, which was
originally identiﬁed as a proapoptotic protein, is strongly
correlated with obesity. The expression pattern and
functions of CIDE-A are well established; however,
little is known about its transcriptional regulation. Since
CIDE-A is considered as a novel target for therapeutic
intervention of obesity and Type II diabetes, a better
understanding of the mechanism responsible for the
expression of this gene may provide new opportunities
for therapy.
In the present study, we aimed to characterize the
mechanism that regulated the tissue- and cell-speciﬁc
expression of the CIDE-A gene. By using 50 ﬂanking
region-luciferase fusion plasmids, we identiﬁed the core
CIDE-A promoter as a 125-bp region located between the
base pairs  137 to  13 that contained two Sp1/Sp3-
binding sites. The activity of the CIDE-A promoter was
greatly reduced when site-directed mutations were intro-
duced in each of these binding sites; this ﬁnding
demonstrated a crucial role of the Sp1/Sp3-binding sites
in CIDE-A promoter activity. In addition, EMSAs also
conﬁrmed that Sp1 and Sp3 could speciﬁcally bind to the
putative binding sites identiﬁed in the minimal region.
In view of this ﬁnding, the fact that the CIDE-A gene was
expressed in a tissue- and cell-speciﬁc manner was rather
confusing because Sp1 and Sp3 are two ubiquitously
expressed mammalian transcription factors that bind to
DNA with similar speciﬁcity and aﬃnity and participate
in the regulation of the expression of genes involved in
almost all cellular processes (20,21). Thus, it appears that
Sp1 and Sp3 alone might not determine tissue- and cell-
speciﬁc expression of the CIDE-A gene. Interestingly, the
basal promoter activity of the core region was observed
even in cells that did not endogenously express CIDE-A.
Figure 8. CpG methylation inhibits the binding of Sp1 and Sp3 to the
CIDE-A promoter in vivo. ChIP was performed using the chromatin
from Hela cells with or without 3 days’ 1uM 5-aza-dC treatment.
Protein–DNA complexes were subjected to immunoprecipitation using
anti-Sp1 or anti-Sp3 antibodies. The normal rabbit IgG was used as
a negative control. Protein-bound immunoprecipitated DNA was eluted
and recovered for the PCR analysis of the CIDE-A promoter region
by using a primer set speciﬁc for the CIDE-A promoter. Input
represents the relative amounts of protein–DNA complex subjected to
immunoprecipitation.
338 Nucleic Acids Research, 2008, Vol. 36, No. 1Similar phenomenon was also observed in previous studies
on CIDE-B, NF1 (neuroﬁbromatosis type 1) and APC
(adenomatous polyposis of the colon) promoters
(11,22,23). Since the transiently transfected constructs
were unlikely to adopt the native chromatin structure, this
observation prompted us to investigate whether DNA
methylation was involved in the mechanisms underlying
the silencing of the CIDE-A gene in non-expressing cells
and tissues.
We investigated the DNA methylation proﬁles of a
portion of the CpG island covering the Sp1/Sp3-binding
sites. Sodium bisulﬁte sequencing analysis revealed that
the CpG sites in the minimal promoter region were
hypomethylated in CIDE-A expressed tissues (heart and
adipose), but they were hypermethylated in CIDE-A
absent or low expressed tissues (liver, spleen and stomach)
and cell lines (Hela, BEL-7404 and HEK-293T cells). The
involvement of methylation in the CIDE-A gene silencing
was further supported by the ﬁnding that cells transfected
by constructs densely methylated by SssI methylase
in vitro showed a signiﬁcant decrease in luciferase
activities. Moreover, we found that after treatment with
the methyltransferase inhibitor 5-aza-dC, the gene expres-
sion was restored in all the CIDE-A non-expressing cells.
In addition, the nuclease accessibility assay demonstrated
that the chromatin conformation around the Sp1/Sp3-
binding sites in the CIDE-A non-expressing cells changed
from ‘closed’ to ‘open’ after 5-aza-dC treatment. We
further used ChIP to determine the levels of two critical
histone H3 modiﬁcations (Ac-H3K9 and di-methyl H3K9)
at CIDE-A gene core promoter. Consistent with the
studies of other genes, we ﬁnd that increased levels of
di-methyl H3K9at CIDE-A promoter correlates with a
lack of gene expression, whereas an increased abundance
of Ac-H3K9 correlates with increased gene expression.
However, no signiﬁcant changes were observed in
CIDE-A expression levels, methylation status or chroma-
tin conformation after the cells were treated with TSA, a
histone deacetylase inhibitor. This observation is consis-
tent with the previous reports on the regulation of
hypermethylated genes such as hMLH1, CDKN2B
(p15INK4B) and CDKN2A (p16INK4) (16). In these
studies, 5-aza-dC treatment induced the expression of
these hypermethylated genes and reversed histone mod-
iﬁcation, whereas TSA treatment did not induce these
changes (16,24). Taken together, all these ﬁndings satisfy
two well-known criteria for deﬁning the role of DNA
methylation in tissue- and cell-speciﬁc gene repression:
(i) CIDE-A was densely methylated in non-expressing
tissue and cells and (ii) induced demethylation resulted in
the activation of CIDE-A.
The methylation of genomic DNA at CpG dinucleo-
tides is a major epigenetic modiﬁcation of the mammalian
genome (25), and it functions in several aspects of gene
expression such as X chromosome inactivation, genomic
imprinting, immobilization of transposons and suppres-
sion of transcriptional noise (26–28). Methylation of CpG
sites in the promoter region is also believed to ensure the
silencing of tissue-speciﬁc genes (29). Several mechanisms
have been proposed for methylation-induced gene repres-
sion. Among these mechanisms, the direct blocking of the
binding of transcription factors to their CpG-containing
binding sites is an important mechanism that contributes
to transcriptional repression. In the case of c-Myb (30),
c-Myc/Myn (31), E2F (32), CREB (cAMP-response
element-binding protein) (33), AP2 (activator protein 2)
(34) and NF- B (nuclear factor  B) (35), methylated CpGs
in their recognition site preclude the binding of the
transcription factor and thereby directly inhibit gene
expression.
Previous studies have shown that the Sp1-binding
aﬃnity to its responding element is not consequentially
aﬀected by DNA methylation, which appears to be pro-
moter dependent. The Sp1-binding aﬃnity to the luteiniz-
ing hormone receptor (LHR) or CLDN4 promoter was not
aﬀected by DNA methylation (36,37). In contrast, in the
Figure 9. Knockdown of Sp1 and Sp3 expression by siRNA reduces
CIDE-A promoter activity. (A) Immunoblotting analysis of Sp1 and
Sp3 protein levels in HEK-293T cells transfected with Sp1 and Sp3
siRNA. Control siRNA was used as negative control and Tublin as a
loading control. (B) The eﬀect of Sp1 or Sp3 siRNA on CIDE-A
promoter activity detected by luciferase reporter assay. HEK-293T cells
were transfected with Sp1 and Sp3 siRNAs individually or simulta-
neously and then transfected again with the luciferase reporter plasmid
p( 137/ 13) and p( 1556/ 137). The activity of each promoter
construct is shown as the luciferase activity relative to that of the
pGL3-Basic vector. Values were normalized for transfection eﬃciency
by cotransfection with the Renilla expression plasmid and are shown as
means SD for three independent experiments.
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Cip1,1 1b-hydroxysteroid dehydrogenase type 2,
GSTP1(glutathioneS-transferase p1)orIGFBP-3(insulin-
like growth factor-binding protein-3), the Sp1-binding
aﬃnity to the respective promoter region was found to be
abolished by DNA methylation (38–41). Because of the
vital roles of Sp1/Sp3 in maintaining CIDE-A basal
promoter activity, we further investigated whether DNA
methylation could impair the binding of Sp1/Sp3 to the
CIDE-Apromoterinnon-expressingcells. Inourstudy,the
ChIP assay clearly showed that the binding of Sp1 and Sp3
to the CIDE-A promoter could be diminished by methyla-
tion of the Sp1/Sp3 motif, similar to that observed for
p21
Cip1, GSTP1 and IGFBP-3 promoters; furthermore,
treatment of Hela cells with 1mM 5-aza-dC for 3 days
markedly enhanced the binding aﬃnity of Sp1/Sp3 along
with restoration of the expression of CIDE-A. We further
conﬁrmed the roles of Sp1 and Sp3 in regulation of CIDE-
A promoter activity by using RNA interference. Consistent
with our reporter assays demonstrating a crucial role for
Sp1/Sp3 sites in CIDE-A promoter activity, Sp1 and Sp3
knockdown signiﬁcantly reduced transcription levels con-
trolled by the CIDE-A promoter. Taken together, our
results clearly indicate that the methylation status of the
CIDE-A promoter correlated well with CIDE-A gene
expression in a subset of cell lines and tissues, and that
DNA methylation was the key mechanism of regulating
tissue- and cell-speciﬁc expression of CIDE-A through
blocking of the binding of Sp1 and Sp3 to the CIDE-A
promoter. Our ﬁndings also suggest that the switch
between transcriptional silencing and expression of the
tissue-speciﬁc gene could depend on varying epigenetic
modiﬁcation, which is driven by basal transcription factors
such as Sp1/Sp3 and activation of the conserved promoter
sites. It would be interesting to investigate the change in the
methylationstatusoftheCIDE-Apromoterduringadipose
diﬀerentiation and to determine whether the regulation of
higher-order chromatin structures by methyl-CpG-binding
proteins such as MeCP1 (42), MeCP2 (43,44) and MBD2
(43,45) is involved in CIDE-A gene silencing in non-
expressing cells and tissues. Such information would
provide further insights into the role of CpG methylation
in the regulation of tissue-speciﬁc expression of the
CIDE-A gene.
In conclusion, our data revealed that DNA methylation
of CpG sites in the CIDE-A promoter was the primary
mechanism through which the transcription of CIDE-A
was silenced or repressed in non-expressing cells and
tissues. In addition, we showed that the Sp1/Sp3
consensus sequence—the critical regulatory elements—
were methylated, and methylation of this motif prohibited
the access of Sp1 and Sp3 transcriptional factors, resulting
in the downregulation of the activity of the CIDE-A
promoter.
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